100 related articles for article (PubMed ID: 12698949)
1. Covalent and noncovalent modifiers of the p53 protein.
Jayaraman L; Prives C
Cell Mol Life Sci; 1999 Jan; 55(1):76-87. PubMed ID: 10065153
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
Hernández Borrero LJ; El-Deiry WS
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators.
Balourdas DI; Markl AM; Krämer A; Settanni G; Joerger AC
Cell Death Dis; 2024 Jun; 15(6):408. PubMed ID: 38862470
[TBL] [Abstract][Full Text] [Related]
4. Bacterial Carriers for Glioblastoma Therapy.
Mehta N; Lyon JG; Patil K; Mokarram N; Kim C; Bellamkonda RV
Mol Ther Oncolytics; 2017 Mar; 4():1-17. PubMed ID: 28345020
[TBL] [Abstract][Full Text] [Related]
5. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.
Micel LN; Tentler JJ; Smith PG; Eckhardt GS
J Clin Oncol; 2013 Mar; 31(9):1231-8. PubMed ID: 23358974
[TBL] [Abstract][Full Text] [Related]
6. Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.
Saha A; Kaul R; Murakami M; Robertson ES
Cancer Biol Ther; 2010 Nov; 10(10):961-78. PubMed ID: 21084867
[TBL] [Abstract][Full Text] [Related]
7. Protopia: a protein-protein interaction tool.
Real-Chicharro A; Ruiz-Mostazo I; Navas-Delgado I; Kerzazi A; Chniber O; Sánchez-Jiménez F; Medina MA; Aldana-Montes JF
BMC Bioinformatics; 2009 Oct; 10 Suppl 12(Suppl 12):S17. PubMed ID: 19828077
[TBL] [Abstract][Full Text] [Related]
8. Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.
Fischer PM
Int J Pept Res Ther; 2006 Mar; 12(1):3-19. PubMed ID: 19617922
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.
Saha A; Murakami M; Kumar P; Bajaj B; Sims K; Robertson ES
J Virol; 2009 May; 83(9):4652-69. PubMed ID: 19244339
[TBL] [Abstract][Full Text] [Related]
10. Knitting and untying the protein network: modulation of protein ensembles as a therapeutic strategy.
Gordo S; Giralt E
Protein Sci; 2009 Mar; 18(3):481-93. PubMed ID: 19241367
[TBL] [Abstract][Full Text] [Related]
11. Beta-peptides with improved affinity for hDM2 and hDMX.
Harker EA; Daniels DS; Guarracino DA; Schepartz A
Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253
[TBL] [Abstract][Full Text] [Related]
12. What induces pocket openings on protein surface patches involved in protein-protein interactions?
Eyrisch S; Helms V
J Comput Aided Mol Des; 2009 Feb; 23(2):73-86. PubMed ID: 18777159
[TBL] [Abstract][Full Text] [Related]
13. SUMO-1 enhancing the p53-induced HepG2 cell apoptosis.
Lu X; Yi J
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):289-91. PubMed ID: 16201274
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells.
Li WD; Wang MJ; Ding F; Yin DL; Liu ZH
World J Gastroenterol; 2005 May; 11(19):2927-31. PubMed ID: 15902730
[TBL] [Abstract][Full Text] [Related]
15. NMR structure of a complex between MDM2 and a small molecule inhibitor.
Fry DC; Emerson SD; Palme S; Vu BT; Liu CM; Podlaski F
J Biomol NMR; 2004 Oct; 30(2):163-73. PubMed ID: 15557803
[TBL] [Abstract][Full Text] [Related]
16. Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level.
Karlsson GB; Jensen A; Stevenson LF; Woods YL; Lane DP; Sørensen MS
Br J Cancer; 2004 Oct; 91(8):1488-94. PubMed ID: 15381928
[TBL] [Abstract][Full Text] [Related]
17. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.
Zheleva DI; Lane DP; Fischer PM
Mini Rev Med Chem; 2003 May; 3(3):257-70. PubMed ID: 12698949
[TBL] [Abstract][Full Text] [Related]
18. Turning the key on p53.
Lane DP; Fischer PM
Nature; 2004 Feb; 427(6977):789-90. PubMed ID: 14985740
[No Abstract] [Full Text] [Related]
19. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
